Warren Buffett is known for owning shares in some of America's leading companies, in industries from financials to oil. One particular area he hasn't invested too heavily in, though, is healthcare -- the risks of drug development, high costs of research, and complexity of the science behind many pharma pipelines are all elements that don't go hand-in-hand with the billionaire's investment strategy.

But there's one thing in particular that Buffett and his team at Berkshire Hathaway may have liked about Johnson Johnson (NYSE: JNJ), their long-term -- and very last -- pharmaceutical holding. And that's the company's track record of dividend growth. Still, Buffett and his fund managers recently sold all of their shares of the pharma giant, marking a complete exit from the industry. Considering Buffett's top stock picking skills and long-term performance, you may be temped to sell or avoid J too. But should you really follow the Oracle of Omaha this time? Let's find out.

Image source: Getty Images.

Continue reading

Source Fool.com